NCIt definition : A conditionally active biologic (CAB) and monoclonal antibody directed against the
human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4;
CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities.
Upon administration and specific activation in the tumor microenvironment (TME) due
to the unique microphysical conditions that are present in the TME, evalstotug targets
and binds to CTLA-4 expressed on T-cells within the TME and inhibits the CTLA-4-mediated
downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated
immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory
receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in
the downregulation of the immune system. By using a CAB anti-CTLA-4 antibody, systemic
toxicity may be reduced.;
UNII : ZT62XSC86F;
CAS number : 2460399-39-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2460399-39-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)